How MDMA's Pharmacology and Pharmacokinetics Drive Desired Effects and Harms

MDMA, used by over 16 million Americans, produces desired effects such as increased energy, elevated mood, bonding, and psychedelic experiences, but also carries risks including liver damage, depressed mood, serotonin syndrome, multiorgan failure, cardiovascular events, and death. Its effects stem from a pharmacologic profile combining methamphetamine-like and mescaline-like actions, plus increased release of cortisol, oxytocin, and antidiuretic hormone. The rave or electronic dance music environment—with warm temperatures, vigorous dancing, loud music, and light shows—accentuates both desirable responses and certain harms. Understanding these factors is essential for education, harm prevention, and treatment.

Study at a glance

Abstract

Abstract 3,4‐Methylenedioxymethamphetamine (MDMA) is an agent of abuse that has been used by over 16 million Americans. Increased energy, elevated mood, bonding with others, and psychedelic effects are desired effects while liver damage, extended depressed mood, sexual assault, rhabdomyolysis, serotonin syndrome, multiorgan failure, cardiovascular events, arrhythmias, and death are possible adverse effects. These desirable and adverse effects of MDMA are extensions of its fascinating pharmacologic and pharmacokinetic profile. In addition to methamphatemine like effects, MDMA also has mescaline like effects and increases the release of cortisol, oxytocin, and antidiuretic hormone. The desirable effects of MDMA are accentuated by the rave or electronic dance music scene where warm temperatures, vigorous dancing, loud music, and light shows accentuate some of the responses. However, the same environment increases the risk of certain harms. Knowledge of the constellation of these factors is needed for education, prevention of harm, and treatment.